David Ebsworth

Dr Ebsworth has served as Non-Executive Chairperson of our board of directors since December 2014.

Dr Ebsworth has significant experience in leadership and management of pharma and biotech companies internationally. Dr Ebsworth currently serves on the boards of Sartorius and Synlab. From 2009 to 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s Executive Committee, positions he held until 2014. In his earlier career, Dr Ebsworth worked with Bayer for over 19 years, heading the Canadian, North American and global pharmaceutical business. Dr Ebsworth received a PhD in industrial relations from the University of Surrey.

Ken Cunningham

Dr Cunningham has served as a Non-Executive Director on our board of directors since September 2015.

Dr Cunningham has over 30 years of experience in the pharmaceutical industry including leadership roles at several companies focused on developing respiratory medicines. He serves as Non-Executive Chairperson of the board of directors of Medherant. Between 2006 and 2010, he was at SkyePharma (now part of Vectura Group), initially as Chief Operating Officer and subsequently as CEO where he was involved in the late-stage development of flutiform for asthma. Previously, he was CEO of Arakis, where he was involved in the early clinical development of glcopyrronium bromide, which is now marketed as Seebri for chronic obstructive pulmonary disease. Dr Cunningham received a degree in medicine from St. Mary’s, Imperial College, London University.

Mahendra Shah

Dr Shah has served as a Non-Executive Director on our board of directors since July 2016.

Dr Shah, Senior Fellow of Vivo Capital, was formerly a Managing Partner at the healthcare investment firm. Dr Shah is also the founder and Executive Chair of Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals), a specialty pharmaceutical company. Dr Shah previously served as a board member of Soleno Therapeutics, Crinetics Pharmaceuticals, Aadi Bioscience and Homology Medicines. He currently serves as a member of the board of directors of several private companies in the biopharmaceutical and biotechnology industries. Dr Shah received his PhD in industrial pharmacy from St John’s University and a Master’s Degree in Pharmacy from LM College of Pharmacy in Gujarat, India.